Lilly Presents Results of Mirikizumab in P-II SERENITY Study for Crohn’s Disease at DDW 2021

 Lilly Presents Results of Mirikizumab in P-II SERENITY Study for Crohn’s Disease at DDW 2021

Lilly Presents Results of Mirikizumab in P-II SERENITY Study for Crohn’s Disease at DDW 2021

Shots:

  • The P-II SERENITY study involves assessing mirikizumab (200/600/1000mg) vs PBO in patients in a ratio (2:1:1:2) with mod. to severely active CD for 12wks.
  • Patients showed improvement in fatigue @12wks. as measured by the mean change in FACIT-Fatigue scores with improvements that sustained up to 1yr. At the end of the 12wks. period, patients treated with mirikizumab who achieved ≥1 point improvement in SES-CD were re-randomized in a ratio (1:1) to continue to receive the same, once-monthly mirikizumab (IV or SC, 300mg), up to 52wks.
  • Three analyses of the RWE data also highlight the burden of fatigue and rectal urgency among people living with UC and CD

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Forbes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post